VEGFA and renal cell carcinoma: Renal cell carcinoma (RCC) has long been characterized by dysregulated metabolic pathways and a highly infiltrated tumor immune microenvironment.[1] Despite breakthroughs in surgical methods and targeted therapies including vascular endothelial growth factor inhibitors and rapamycin inhibitors or in combination with immune checkpoints blockade, oncologic outcomes still fall far short of expectations partly resulting from the high frequency of immunoevasion in RCC.[2]